Anaplastic large cell lymphoma of bone--is it a bad tumor?

Pediatr Blood Cancer. 2007 Apr;48(4):473-6. doi: 10.1002/pbc.20542.

Abstract

A teenage boy presented with a CD30-positive anaplastic large cell lymphoma (ALCL) affecting his scapula and was successfully treated with chemotherapy. His clinical features and outcome were compared with other cases described in the literature. A further review of 11 ALCL cases with bony involvement treated in the UK since 1990, including two with primary bone disease, did not suggest an unfavorable treatment outcome. This finding will need to be confirmed by further study on a larger patient cohort with primary bone ALCL.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Activin Receptors, Type II / analysis
  • Activin Receptors, Type II / genetics
  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics
  • Bone Neoplasms / chemistry
  • Bone Neoplasms / diagnosis
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / epidemiology
  • Bone Neoplasms / genetics
  • Bone Neoplasms / pathology*
  • Child
  • Child, Preschool
  • Cohort Studies
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Ifosfamide / administration & dosage
  • Infant
  • Ki-1 Antigen / analysis
  • Lymphoma, Large-Cell, Anaplastic / chemistry
  • Lymphoma, Large-Cell, Anaplastic / diagnosis
  • Lymphoma, Large-Cell, Anaplastic / drug therapy
  • Lymphoma, Large-Cell, Anaplastic / epidemiology
  • Lymphoma, Large-Cell, Anaplastic / genetics
  • Lymphoma, Large-Cell, Anaplastic / pathology*
  • Magnetic Resonance Imaging
  • Male
  • Methotrexate / administration & dosage
  • Prognosis
  • Remission Induction
  • Scapula / pathology*
  • Treatment Outcome
  • United Kingdom / epidemiology

Substances

  • Biomarkers, Tumor
  • Ki-1 Antigen
  • Cytarabine
  • Etoposide
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • ACVRL1 protein, human
  • Activin Receptors, Type II
  • Ifosfamide
  • Methotrexate